199 related articles for article (PubMed ID: 18635746)
1. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
2. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
3. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
5. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Matsunaga T; Kezuka C; Morikawa Y; Suzuki A; Endo S; Iguchi K; Miura T; Nishinaka T; Terada T; El-Kabbani O; Hara A; Ikari A
Biol Pharm Bull; 2015; 38(9):1309-19. PubMed ID: 26328486
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.
Hofman J; Skarka A; Havrankova J; Wsol V
Biochem Pharmacol; 2015 Aug; 96(3):168-78. PubMed ID: 25986883
[TBL] [Abstract][Full Text] [Related]
9. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
11. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
[TBL] [Abstract][Full Text] [Related]
12. Chinese hamster monomeric carbonyl reductases of the short-chain dehydrogenase/reductase superfamily.
Miura T; Nishinaka T; Takama M; Murakami M; Terada T
Chem Biol Interact; 2009 Mar; 178(1-3):110-6. PubMed ID: 18983989
[TBL] [Abstract][Full Text] [Related]
13. Carbonyl reduction of mequindox by chicken and porcine cytosol and cloned carbonyl reductase 1.
Tang X; Mu P; Wu J; Jiang J; Zhang C; Zheng M; Deng Y
Drug Metab Dispos; 2012 Apr; 40(4):788-95. PubMed ID: 22266778
[TBL] [Abstract][Full Text] [Related]
14. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
15. Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3.
Staab CA; Hartmanová T; El-Hawari Y; Ebert B; Kisiela M; Wsol V; Martin HJ; Maser E
Chem Biol Interact; 2011 May; 191(1-3):95-103. PubMed ID: 21256830
[TBL] [Abstract][Full Text] [Related]
16. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
17. The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A.
Hanušová V; Boušová I; Pakostová A; Skálová L
Xenobiotica; 2012 Jun; 42(6):571-9. PubMed ID: 22217270
[TBL] [Abstract][Full Text] [Related]
18. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
Miura T; Nishinaka T; Terada T
Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
[TBL] [Abstract][Full Text] [Related]
19. Human Tissue Distribution of Carbonyl Reductase 1 Using Proteomic Approach With Liquid Chromatography-Tandem Mass Spectrometry.
Hua W; Zhang H; Ryu S; Yang X; Di L
J Pharm Sci; 2017 May; 106(5):1405-1411. PubMed ID: 28161444
[TBL] [Abstract][Full Text] [Related]
20. Flavonoids as inhibitors of human carbonyl reductase 1.
Carlquist M; Frejd T; Gorwa-Grauslund MF
Chem Biol Interact; 2008 Jul; 174(2):98-108. PubMed ID: 18579125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]